Tracking a bleeding disorder treatment in real-world use

This is a real-world monitoring study of OBIZUR, a medication used to treat acquired hemophilia A—a rare bleeding disorder that develops later in life. Researchers are collecting information from patients in South Korea who are already receiving OBIZUR as part of their regular medical care. The study gathers both past treatment records and ongoing health information to understand how well the medication works and how safe it is when used in everyday practice.

Acquired hemophilia A is a serious condition where the body stops producing enough clotting factor, leading to dangerous bleeding. After a medication is approved for use, health authorities require ongoing monitoring to ensure it continues to be safe and effective in real patients. This study fills that requirement by collecting data from actual patients receiving this treatment.